Difference between revisions of "Ganitumab (AMG-479)"
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
Warner-admin (talk | contribs) m (Warner-admin moved page Ganitumab (AMG 479) to Ganitumab (AMG-479) without leaving a redirect) |
||
| (7 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
| − | Class/mechanism: Human monoclonal antibody that targets IGF-1R (insulin-like growth factor 1 receptor). | + | Class/mechanism: Human monoclonal antibody that targets IGF-1R (insulin-like growth factor 1 receptor). IGF-1R plays a role in cell survival and cell cycle progression via the PI3K/Akt pathway. Ganitumab's mechanism of action may involve: 1. inhibition of binding of IGF-1 and IGF-2 to IGF-1R; 2. blocking the action of IGF-1R homodimers and IGF-1R/INSR (insulin receptor) hybrid receptors; 3. downregulating expession of IGF-1R.<ref>[http://www.amgen.com/science/pipe.html Amgen drug development pipeline]</ref><ref>[http://mct.aacrjournals.org/content/8/5/1095.long AMG 479, a fully human anti–insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| Line 10: | Line 8: | ||
==Patient drug information== | ==Patient drug information== | ||
No information available | No information available | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Code name:''' AMG-479 | ||
==References== | ==References== | ||
| Line 15: | Line 16: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| − | + | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | + | ||
[[Category:Anti-IGF-1R antibodies]] | [[Category:Anti-IGF-1R antibodies]] | ||
| − | [[Category:Investigational]] | + | [[Category:Investigational drugs]] |
Latest revision as of 00:30, 29 July 2023
General information
Class/mechanism: Human monoclonal antibody that targets IGF-1R (insulin-like growth factor 1 receptor). IGF-1R plays a role in cell survival and cell cycle progression via the PI3K/Akt pathway. Ganitumab's mechanism of action may involve: 1. inhibition of binding of IGF-1 and IGF-2 to IGF-1R; 2. blocking the action of IGF-1R homodimers and IGF-1R/INSR (insulin receptor) hybrid receptors; 3. downregulating expession of IGF-1R.[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.
Patient drug information
No information available
Also known as
- Code name: AMG-479